Chrysos Corporation Posts Strong FY26 Growth on Rising PhotonAssay Demand
Chrysos Corporation Limited (ASX: C79) recorded robust growth in FY26 as stronger demand and higher utilisation of its PhotonAssay technology supported financial and operational performance. Revenue rose 33% year-on-year to AU$88.1 million, while EBITDA increased 68% to AU$27.2 million. Improved operating efficiency also lifted the EBITDA margin to 31%, compared with 24% in FY25.
Operational activity strengthened considerably, with 11.3 million samples processed during the year, representing 67% annual growth. Chrysos deployed seven new units and secured 24 lease agreements during FY26. Four additional agreements signed after year-end increased contracted units to 87.
The company generated AU$17.9 million in operating cash inflow and maintained substantial funding capacity. For FY27, management expects revenue between AU$108 million and AU$118 million and EBITDA between AU$35 million and AU$42 million, supported by further deployments, growing utilisation and broader global adoption.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Chrysos Corporation Posts Strong FY26 Growth on Rising PhotonAssay Demand
Chrysos Corporation Limited (ASX: C79) recorded robust growth in FY26 as stronger demand and higher utilisation of its PhotonAssay technology supported financial and operational performance. Revenue rose 33% year-on-year to AU$88.1 million, while EBITDA increased 68% to AU$27.2 million. Improved operating efficiency also lifted the EBITDA margin to 31%, compared with 24% in FY25.
Operational activity strengthened considerably, with 11.3 million samples processed during the year, representing 67% annual growth. Chrysos deployed seven new units and secured 24 lease agreements during FY26. Four additional agreements signed after year-end increased contracted units to 87.
The company generated AU$17.9 million in operating cash inflow and maintained substantial funding capacity. For FY27, management expects revenue between AU$108 million and AU$118 million and EBITDA between AU$35 million and AU$42 million, supported by further deployments, growing utilisation and broader global adoption.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au